Lenvatinib is a multikinase inhibitor that suppresses vascular endothelial growth factor
receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor …

Hepatocellular carcinoma (HCC) is one of the most common cancers and the third leading
cause of death worldwide. surgery, transarterial chemoembolization (TACE), systemic …

Lenvatinib is a tyrosine kinase inhibitor that prevents the formation of new blood vessels
namely by inhibiting tyrosine kinase enzymes as the name suggests. Specifically, Lenvatinib …

Lenvatinib, a multitargeted tyrosine kinase inhibitor (TKI), is one of the preferred targeted
drugs for the treatment of advanced hepatocellular carcinoma (aHCC). Since the REFLECT …

Checkpoint inhibitors are monoclonal antibodies that elicit an anti-tumor response by
stimulating immune system. Their use has improved the treatment of different types of cancer …

Most cases of hepatocellular carcinoma (HCC) are able to be diagnosed through regular
surveillance in an identifiable patient population with chronic hepatitis B or cirrhosis …

Hepatocellular carcinoma (HCC) is a common malignant tumor with complex survival
mechanism and drug resistance, resulting in cancer-related high mortality in the world …

Simple Summary Portal hypertension (PH) and hepatocellular carcinoma (HCC) are major
complications of liver cirrhosis with a detrimental impact on patient outcomes that share …

Lenvatinib, an FDA-approved first-line oral multi-kinase inhibitor for advanced
hepatocellular carcinoma (aHCC), has demonstrated promise for treatment. Nevertheless …

Lenvatinib is a multi-target tyrosine kinase inhibitor widely used in the treatment of
hepatocellular carcinoma (HCC). Its primary mechanism of action involves inhibiting signal …